NasdaqGS:DFTXPharmaceuticals
Definium Therapeutics (DFTX) Is Up 6.0% After Strong DT120 Data Amid Wider Q2 Net Loss
In the past week, Definium Therapeutics, Inc. reported a wider Q2 2026 net loss of US$158.99 million with basic and diluted loss per share of US$1.44, while also highlighting strong Phase III DT120 ODT data in major depressive disorder and progress toward pivotal generalized anxiety disorder readouts.
The company also released a large real‑world claims analysis showing high discontinuation and switching rates in generalized anxiety disorder treatment, underscoring substantial unmet need that...